Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLONASDAQ:AVDLNASDAQ:NTLANYSE:RCUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.06-2.8%$1.41$0.86▼$3.78$231.86M0.63.33 million shs2.85 million shsAVDLAvadel Pharmaceuticals$9.13+2.8%$8.30$6.38▼$17.30$883.23M1.41.23 million shs818,988 shsNTLAIntellia Therapeutics$9.16-3.2%$7.98$5.90▼$28.18$948.82M2.332.56 million shs2.18 million shsRCUSArcus Biosciences$9.05+3.0%$8.23$6.50▼$18.98$929.67M0.88848,146 shs901,320 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics-2.75%-4.50%-34.16%-51.15%-60.15%AVDLAvadel Pharmaceuticals+2.82%+1.33%+9.87%+8.56%-42.29%NTLAIntellia Therapeutics-3.17%+7.76%+13.02%-24.73%-64.73%RCUSArcus Biosciences+3.02%+5.67%+11.39%-18.22%-46.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLOAllogene Therapeutics3.5734 of 5 stars4.53.00.00.02.33.30.6AVDLAvadel Pharmaceuticals2.2377 of 5 stars3.51.00.00.03.61.70.6NTLAIntellia Therapeutics4.6333 of 5 stars4.31.00.04.73.92.51.3RCUSArcus Biosciences3.5312 of 5 stars4.53.00.00.02.54.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.90Moderate Buy$8.44696.65% UpsideAVDLAvadel Pharmaceuticals 3.00Buy$19.43112.80% UpsideNTLAIntellia Therapeutics 2.67Moderate Buy$36.90302.84% UpsideRCUSArcus Biosciences 2.91Moderate Buy$25.67183.77% UpsideCurrent Analyst Ratings BreakdownLatest ALLO, NTLA, RCUS, and AVDL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025NTLAIntellia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/19/2025NTLAIntellia TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$10.00 ➝ $10.005/15/2025ALLOAllogene TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$8.00 ➝ $4.005/14/2025ALLOAllogene TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$9.00 ➝ $7.005/14/2025ALLOAllogene TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$14.00 ➝ $10.005/14/2025ALLOAllogene TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.005/14/2025ALLOAllogene TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$10.00 ➝ $9.005/14/2025ALLOAllogene TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$12.00 ➝ $9.005/14/2025ALLOAllogene TherapeuticsCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/12/2025NTLAIntellia TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$55.00 ➝ $45.005/9/2025NTLAIntellia TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$14.00 ➝ $10.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$22K10,538.86N/AN/A$3.04 per share0.35AVDLAvadel Pharmaceuticals$194.45M4.54N/AN/A$0.98 per share9.32NTLAIntellia Therapeutics$45.57M20.82N/AN/A$11.73 per share0.78RCUSArcus Biosciences$141M6.79N/AN/A$6.17 per share1.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$327.27M-$1.23N/AN/AN/AN/A-52.13%-41.29%8/6/2025 (Estimated)AVDLAvadel Pharmaceuticals-$160.28M-$0.27N/A152.17N/A-52.53%-93.34%-44.77%N/ANTLAIntellia Therapeutics-$481.19M-$5.23N/AN/AN/AN/A-49.34%-40.27%N/ARCUSArcus Biosciences-$307M-$4.19N/AN/AN/A-102.66%-45.59%-22.38%N/ALatest ALLO, NTLA, RCUS, and AVDL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ALLOAllogene Therapeutics-$0.28-$0.28N/A-$0.28$0.00 millionN/A5/8/2025Q1 2025NTLAIntellia Therapeutics-$1.26-$1.10+$0.16-$1.10$11.39 million$16.63 million5/7/2025Q1 2025AVDLAvadel Pharmaceuticals-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 million5/6/2025Q1 2025RCUSArcus Biosciences-$1.02-$1.14-$0.12-$1.14$38.61 million$28.00 million3/13/2025Q4 2024ALLOAllogene Therapeutics-$0.34-$0.28+$0.06-$0.28$0.01 millionN/A2/25/2025Q4 2024RCUSArcus Biosciences-$1.17-$1.03+$0.14-$1.03$29.38 million$36.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A9.359.35AVDLAvadel PharmaceuticalsN/A2.972.60NTLAIntellia TherapeuticsN/A6.736.73RCUSArcus Biosciences0.085.245.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%AVDLAvadel Pharmaceuticals69.19%NTLAIntellia Therapeutics88.77%RCUSArcus Biosciences92.89%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%AVDLAvadel Pharmaceuticals4.80%NTLAIntellia Therapeutics3.10%RCUSArcus Biosciences12.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310218.73 million158.72 millionOptionableAVDLAvadel Pharmaceuticals7096.74 million91.74 millionOptionableNTLAIntellia Therapeutics600103.58 million98.59 millionOptionableRCUSArcus Biosciences500105.89 million80.26 millionOptionableALLO, NTLA, RCUS, and AVDL HeadlinesRecent News About These CompaniesWoodline Partners LP Purchases 45,497 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)May 22 at 6:17 AM | marketbeat.comSuvretta Capital Management LLC Has $8.58 Million Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS)May 19, 2025 | marketbeat.comPoint72 Asset Management L.P. Sells 440,794 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)May 19, 2025 | marketbeat.comAmeriprise Financial Inc. Boosts Stake in Arcus Biosciences, Inc. (NYSE:RCUS)May 17, 2025 | marketbeat.comParkman Healthcare Partners LLC Acquires 248,035 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)May 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS)May 16, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Invests $6.93 Million in Arcus Biosciences, Inc. (NYSE:RCUS)May 16, 2025 | marketbeat.comWhy Precision BioSciences, Inc.’s (DTIL) Stock Is Down 9.90%May 15, 2025 | aaii.comCubist Systematic Strategies LLC Grows Position in Arcus Biosciences, Inc. (NYSE:RCUS)May 13, 2025 | marketbeat.comQ2 EPS Estimates for Arcus Biosciences Cut by HC WainwrightMay 11, 2025 | marketbeat.comQ2 Earnings Forecast for Arcus Biosciences Issued By WedbushMay 11, 2025 | marketbeat.comRaymond James Financial Inc. Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS)May 11, 2025 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Position Increased by Algert Global LLCMay 10, 2025 | marketbeat.comArcus Biosciences (NYSE:RCUS) Shares Gap Down Following Weak EarningsMay 9, 2025 | marketbeat.comWells Fargo & Company Lowers Arcus Biosciences (NYSE:RCUS) Price Target to $26.00May 9, 2025 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Dimensional Fund Advisors LPMay 9, 2025 | marketbeat.comBraidwell LP Buys Shares of 802,100 Arcus Biosciences, Inc. (NYSE:RCUS)May 8, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Sells 538,841 Shares of Arcus Biosciences, Inc. (NYSE:RCUS)May 8, 2025 | marketbeat.comRenaissance Technologies LLC Lowers Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)May 8, 2025 | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Q1 2025 Earnings Call TranscriptMay 7, 2025 | msn.comQ1 2025 Arcus Biosciences Inc Earnings CallMay 7, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?By Leo Miller | May 6, 2025View Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?ALLO, NTLA, RCUS, and AVDL Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.06 -0.03 (-2.75%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.06 0.00 (-0.09%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Avadel Pharmaceuticals NASDAQ:AVDL$9.13 +0.25 (+2.82%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$9.10 -0.03 (-0.32%) As of 05/23/2025 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Intellia Therapeutics NASDAQ:NTLA$9.16 -0.30 (-3.17%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$9.13 -0.03 (-0.33%) As of 05/23/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.Arcus Biosciences NYSE:RCUS$9.04 +0.27 (+3.02%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$9.02 -0.02 (-0.22%) As of 05/23/2025 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
